The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 7,994 studies for COVID-19 across more than 10 countries. 468 are recruiting or about to start. 6,709 of them are mainly about COVID-19 (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Post-Acute COVID-19 Syndrome too: 8,396 studies, 618 open.
ClinicalTrials.gov finds 10,274 studies for COVID-19.How that becomes 7,993 here
This page counts the studies the registry files under COVID-19, and those it files under no condition that list COVID-19themselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count
10,274Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−167List COVID-19 as a condition, but the registry did not file them under itMost often written as “COVID-19 Pneumonia” (31), “COVID-19 Respiratory Infection” (25), and “COVID-19 Acute Respiratory Distress Syndrome” (13). The registry filed them under other conditions only, most often Respiratory Distress Syndrome (12) and Influenza, Human (12).
−1,717Match it another way1,676 name it in the title, 21 in a keyword, and 20 by a synonym or other text the search reads.
7,992Counted here and found by its search417 of them list COVID-19 in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 39 programs from 28 companies, 32 with this as their studies’ main aim; 6 with a live phase 3 study; 12 primary completions in the next 12 months. Compare BioNTech, Moderna and Pfizer here →
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 5 in phase 3 with the nearest primary completion, of 39 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (12)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
26 Nov 2026 est.NVX-CoV2373 adjuvated lipid nanoparticle· Sanofi · Phase 4main aimNCT07861542 Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 — primary endpoint: Geometric Mean Fold Rise (GMFR) in pseudovirus neutralizing antibody titers (ID50) against the Omicron subvariant included in the vaccine formulation from pre-vaccination to 28 days post-vaccination. · 669 enrolled
11 Dec 2026 est.MRNA-1283, 2019-nCoV Vaccine mRNA-1273· Moderna, Inc. · Phase 4main aimNCT07863635 A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations — primary endpoint: Geometric Mean Titer (GMT) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant Formulation · 600 enrolled
31 Dec 2026 est.2019-nCoV Vaccine mRNA-1273· Moderna, Inc. · Phase 4main aimNCT06585241 A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations — primary endpoint: mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Geometric Mean Value of Neutralizing Antibody Against COVID-19 Variants · 1,144 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in COVID-19 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
148studies finish main data collection within a year11 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger. 91 (26%) take children under 18. 12 (3%) are for women only and 1 (<1%) for men only; 135 (38%) take healthy volunteers.
Across all 7,994 studies, recruiting or not: 22% stop at 75 or younger and 16% at 65; 17% take children; 2% are for women only and 1% for men only; 34% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long COVID-19 studies take
Of 583 phase 2 interventional studies under COVID-19, half reached primary completion within 9 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
7 mo3–15 · 384 studies
6 mo2–12 · 233 studies
11 mo5–19 · 151 studies
Phase 1/2
11 mo4–20 · 187 studies
10 mo5–19 · 80 studies
11 mo3–21 · 107 studies
Phase 2
9 mo5–16 · 583 studies
8 mo5–13 · 224 studies
11 mo5–18 · 359 studies
Phase 2/3
11 mo5–19 · 168 studies
10 mo5–18 · 73 studies
11 mo5–22 · 95 studies
Phase 3
9 mo4–17 · 453 studies
8 mo4–16 · 168 studies
10 mo5–19 · 285 studies
Phase 4
8 mo4–18 · 189 studies
5 mo3–12 · 44 studies
9 mo5–19 · 145 studies
Interventional, no phase
9 mo3–19 · 1,475 studies
5 mo2–11 · 138 studies
9 mo3–20 · 1,337 studies
Observational
13 mo5–29 · 1,775 studies
10 mo3–19 · 134 studies
14 mo5–30 · 1,641 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.